PetPace Responds to Whistle Shutdown with Exclusive Offer on PetPace Collar as a Smarter Solution for Health, Wellbeing and GPS Tracking
Article content
BURLINGTON, Mass. — PetPace announced today that, following the acquisition of Whistle and the confirmation that all Whistle smart collars will be shut down by August 31, 2025, many pet owners are now facing the challenge of finding a reliable solution to continue monitoring their pets' location and health. In response, PetPace is extending an unprecedented opportunity to Whistle pet parents, inviting them to transition to the PetPace smart collar—an advanced GPS and AI health monitoring device that significantly surpasses basic activity trackers in both features and data insights.
Article content
Unlike traditional collars that focus primarily on activity, PetPace offers a clinically validated health tracking platform with a broader scope of data, including vital signs, behavior trends, and early indicators of health issues. Whistle users are encouraged to explore this limited time offer and experience the enhanced peace of mind that comes with a truly comprehensive pet health and safety solution.
Article content
'In the wake of the acquisition of Whistle, a major disruption is underway in the pet tech world: all Whistle smart collars will be deactivated, leaving pet owners to seek out a replacement for health and location tracking tools. PetPace warmly welcomes all whistle customers to experience how a superior and real health monitoring collar can provide AI predictive healthcare monitoring with vet/patient connectivity,' said Avner Schneur, Cofounder and Chairman of the Board.
As a friendly and empathetic gesture to Whistle pet parents looking for a more advanced, dependable alternative, PetPace is offering our deepest discount yet at $80 off the PetPace collar + your first month free exclusively for verified Whistle collar users. Apply here: https://petpace.com/whistle-offer/ PetPace: More Than a GPS and Activity Tracking Collar For those who've come to rely on the location tracking of Whistle, PetPace delivers that and much more. While Whistle collars primarily focused on GPS and basic activity tracking, PetPace takes pet care significantly further by offering a comprehensive suite of health and behavior monitoring tools that were never available on Whistle devices.
With PetPace, pet parents gain access to:
Article content
Live GPS Tracking – Keep your pet safe with accurate, real-time location monitoring comparable to Whistle's core feature.
Vital Health Metrics – Unlike Whistle, PetPace continuously monitors key physiological indicators such as heart rate, heart rate variability (HRV), respiration, body temperature, and calorie burn—providing a much deeper understanding of your pet's health.
Advanced Behavioral Monitoring – PetPace uses AI to detect patterns in posture, sleep quality, activity levels, and stress—data Whistle users never had access to.
Smart Alerts and Predictive Health Insights – Proprietary algorithms analyze the collected data and send early warnings about possible illness or distress, helping you intervene before a condition worsens.
Veterinary Integration – PetPace offers the option to share health data directly with your veterinarian for faster, more informed care—something not supported by Whistle.
Proven, Research-Based Technology – Used in veterinary hospitals, clinical studies, and academic research settings around the world, PetPace is a medically trusted solution, not just a consumer gadget.
Built to Last – With no planned obsolescence or forced shutdowns, PetPace is a long-term investment in your pet's wellbeing
Article content
Article content
Whether you're coming from Whistle or just beginning your search for better pet care tools, PetPace offers a unique combination of technology, reliability, and peace of mind that's in a class of its own.
How to Redeem the Offer:
Article content
Offer valid through September 15, 2025, or while supplies last.
Article content
About PetPace
Article content
PetPace, based in Burlington, MA, is the leading provider of the most advanced, award-winning technology in holistic pet health solutions. Designed by vets for home use, the PetPace collar is dedicated to enhancing pet wellness through the world's most advanced wearable technology. Our patented AI/ML-powered smart collar continuously collects near real-time physiological and behavioral data, enabling early detection of health issues and redefining predictive pet care. Composed of veterinarians, IoT professionals, engineers, AI experts, and data specialists, our team collaborates with top universities and research institutes worldwide. Trusted by veterinarians, researchers, and pet owners, PetPace is dedicated to protecting and improving pet health. For more information visit:
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact:
Article content
Article content
Margie Adelman
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
18 minutes ago
- National Post
Access Advance Extends Founding Licensee Incentives for Video Distribution Patent Pool Through September 30, 2025
Article content BOSTON — Access Advance LLC today announced an extension of its Founding Licensee incentive program for the Video Distribution Patent (VDP) Pool through September 30, 2025. The incentive program, which originally concluded on June 30, 2025, offers significant savings in royalty payments for video streaming providers seeking comprehensive video codec licensing coverage across HEVC, VVC, VP9, and AV1 technologies. The VDP Pool Licensors have approved this extension to give potential Licensees additional time to qualify for the Founding Licensee benefits. Article content Founding Licensees will receive a 25% reduction in standard royalty rates and a complete waiver of back royalties through 2024. The extension gives potential licensees an additional period to qualify for these benefits by signing a license. The extension responds to continued market interest from video distributors evaluating the VDP Pool's one-stop licensing solution following the recent announcement of major industry participants including ByteDance, Kuaishou, NTT Docomo, and Tencent joining as Licensees of the VDP Pool. Article content Article content 'The strong initial response to our VDP Pool launch demonstrates the market's need for simplified video codec licensing,' said Peter Moller, CEO of Access Advance. 'By extending these Founding Licensee benefits, we're providing additional time for video streaming providers to evaluate how the VDP Pool can simplify and optimize their patent licensing while delivering meaningful savings in royalty payments. Some companies have asked us to extend the qualifying date for Founding Licensee incentives to December 31, 2025, but the Licensors have not yet made a decision about that request.' Article content Interested companies are encouraged to promptly contact Access Advance at licensing@ and lock in the Founding Licensee incentives before the current September 30, 2025 deadline. Article content About Access Advance: Article content Access Advance LLC is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers. Article content Access Advance manages and administers the HEVC Advance Patent Pool for licensing over 27,500 patents essential to H.265/HEVC technology and the VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. The company's Multi-Codec Bridging Agreement provides eligible licensees with a single discounted royalty rate structure for licensees participating in both the HEVC Advance and VVC Advance pools. In addition, Access Advance offers the VDP Pool, a comprehensive licensing solution for video streaming services covering HEVC, VVC, VP9, and AV1 codecs. For more information, please visit: Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Meredith Hollander Article content Article content Article content Email: Article content press@ Article content Article content Website: Article content Article content Article content
Globe and Mail
18 minutes ago
- Globe and Mail
Buy, Sell or Hold Astera Labs Stock? Key Tips Ahead of Q2 Earnings
Astera Labs ALAB is set to report its second-quarter 2025 results on Aug. 5. For the to-be-reported quarter, ALAB expects revenues between $170 million and $175 million, suggesting an increase between 7% and 10% year over year. Earnings are expected between 32 cents and 33 cents per share. The Zacks Consensus Estimate for second-quarter revenues is currently pegged at $172.7 million, indicating an increase of 124.7% from the figure reported in the year-ago quarter. The consensus mark for earnings is currently pegged at 33 cents per share, unchanged over the past 30 days and suggests massive 153.85% growth over the figure reported in the year-ago quarter. ALAB's earnings beat the Zacks Consensus Estimate in all the trailing four quarters, the average earnings surprise being 28.41%. Let's see how things are shaping up prior to this announcement. Factors to Note for ALAB's Q2 Earnings Astera Labs expects accelerated shipments of Scorpio P-Series switches and Aries 6 retimers on a customized rack-scale AI platform based on market-leading GPUs to boost top-line growth. Scorpio revenues are expected to grow sequentially in the second quarter. Astera Labs is benefiting from strong demand for Aries and Taurus product families, both expected to grow on a sequential basis in the second quarter of 2025. Diversification across both GPU and custom ASIC-based systems for a variety of applications, including scale-up and scale-out connectivity, is a key catalyst for ALAB's Aries product family. Continued deployment of AI and general-purpose systems at leading hyperscaler customers is benefiting the Taurus system. However, uncertainty over tariff-related issues and stiff competition from the likes of Credo Technology CRDO and Broadcom AVGO are major headwinds. The company continues to invest in product development to stay ahead of the competition. In first-quarter 2025, research and development (R&D) expenses jumped 20% year over year to $64.6 million. Operating expense is expected to be between $73 million and $75 million in the second quarter of 2025, driven by higher R&D expenses. ALAB Shares Underperform Sector Astera Labs shares have dropped 1% year to date, underperforming the broader Zacks Computer and Technology sector's return of 9.1% and the Zacks Internet Software industry's return of 17.5%. ALAB Stock's Performance Astera Labs stock is not so cheap, as the Value Score of F suggests a stretched valuation at this moment. In terms of the forward 12-month Price/Sales, ALAB is trading at 26.26X, higher than the industry's 5.65X. Price/Sales (F12M) Astera Labs is currently trading above the 50-day and 200-day moving averages, indicating a bullish trend. ALAB Trades Above 50-Day and 200-Day SMAs Strong Portfolio Aids Astera Labs Amid Growing Competition Astera Labs has emerged as a key player in next-gen data center connectivity with a full-stack portfolio spanning PCIe 6.0, Ultra Accelerator (UA) Link, and CXL 3.0. Apart from shipping PCIe Gen 6 Scorpio P-Series Smart Fabric Switches, Aries 6 PCIe/CXL Smart Retimers, and Aries 6 PCIe Smart Cable Modules, the company added Aries 6 PCIe Smart Gearboxes. The addition of PCIe 6 over Optics Technology is noteworthy. Astera Labs plans to provide a broad portfolio of connectivity solutions for the entire AI rack through purpose-built silicon hardware and software to support computing platforms based on both custom ASICs and merchant GPUs is a key catalyst. UA Link, which combines the memory semantics of PCIe and the fast speed of Ethernet, but is devoid of the software complexity and performance limitations of Ethernet, is a game-changer. ALAB expects to deliver UA Link solutions in 2026 to solve scale-up connectivity challenges for next-generation AI infrastructure. The growing proliferation of UA Link is expected to be a multibillion-dollar additional market opportunity for Astera Labs by 2029. A rich partner base that includes NVIDIA NVDA, Alchip and Wistron is noteworthy. Astera Labs has showcased the first end-to-end PCIe 6 interoperability with NVIDIA's Blackwell GPU and Micron's NVMe SSD, with both Aries 6 PCIe Smart Retimer and Scorpio-P PCIe SmartFabric Switch. ALAB is advancing next-gen data center infrastructure with the introduction of a PCIe 6-ready reference design based on NVIDIA Blackwell-based MGX platform that leverages Scorpio Smart Fabric Switches for AI and cloud infrastructure. ALAB has announced a collaboration with NVIDIA to provide scale-up connectivity solutions for the new NVIDIA NVLink Fusion ecosystem. However, Astera Labs is facing stiff competition from both Broadcom and Credo Technology. Broadcom's launch of PCIe Gen 6 portfolio, featuring high-port switches and retimers tested for interoperability with partners like Micron and Teledyne LeCroy, is a noteworthy development. Credo Technology continues to gain share in the optical segment, with a major DSP win for an 800G transceiver and the launch of ultra-low-power optical DSPs based on 5nm technology. It also reported a healthy pipeline of PCIe Gen6 AECs and retimers, with further customer wins expected to support fiscal 2026 growth. Conclusion Astera Labs benefits from a strong portfolio and partner base amid rising competition and tariff uncertainties. A stretched valuation somewhat dims the stock's appeal ahead of second-quarter 2025 results. ALAB currently has a Zacks Rank #3 (Hold), which implies that investors should wait for a more favorable entry point to accumulate the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. NVIDIA Corporation (NVDA): Free Stock Analysis Report Broadcom Inc. (AVGO): Free Stock Analysis Report Astera Labs, Inc. (ALAB): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Ibogaine by David Dardashti Warns of Kratom's ‘Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
WESTCHESTER, FL - August 4, 2025 - As the FDA intensifies its crackdown on the potent kratom compound 7-hydroxymitragynine (7-OH), the addiction treatment center Ibogaine by David Dardashti is issuing a critical warning based on alarming clinical trends. The clinic's founder, David Dardashti, is speaking out about the substance's deceptive role as a gateway to more dangerous opioids, based on a sharp increase in patients seeking treatment for kratom dependency at his facility. The recent FDA actions targeting concentrated 7-OH products—dubbed 'legal morphine' by some researchers—underscore a danger the clinical team at Ibogaine by David Dardashti sees daily. The clinic has witnessed a significant increase in patients arriving with a primary or secondary addiction to kratom, often after being misled by marketing that promotes it as a safe, herbal alternative to opioids. This firsthand clinical data forms the basis for their urgent public warning. 'We are seeing a disturbing pattern,' states David Dardashti. 'Patients come to us after starting with kratom, thinking it's a safe, natural remedy. They don't realize they are developing a true opioid dependency until it's too late. The initial effects fade, tolerance builds, and suddenly they are facing a full-blown addiction with severe withdrawals. The next logical step for many is to seek out something stronger and deadlier, like fentanyl. We are on the front lines of this trend, and it is alarming.' As referenced in recent reports, experts confirm that while the kratom leaf itself may be mild, concentrated extracts containing 7-OH are significantly more potent and act as pure opioids. This creates the dangerous cycle of dependency that the clinic observes. Users require ever-increasing doses, eventually finding that the legal substance no longer satisfies the addiction it created, driving them toward the illicit drug market. Despite the alarming trend, the team at Ibogaine by David Dardashti reports significant success in treating kratom addiction and offers a message of hope. Based on extensive clinical experience, the center has found a notable distinction in the recovery process for these patients. 'The good news in this growing crisis is that we've found that individuals dependent on kratom can be brought back to sobriety with less difficulty than those entrenched in long-term Suboxone or fentanyl use,' Dardashti explains. 'Ibogaine therapy works to reset the brain's neurotransmitters and interrupt addiction at the source. For our kratom patients, the process is often smoother and the path to a full recovery is remarkably clear. Our goal is to intervene effectively before the addiction escalates into a far more tragic story.' About Ibogaine by David Dardashti: Ibogaine by David Dardashti is a leading treatment center dedicated to helping individuals overcome chemical dependency through a unique combination of ibogaine therapy and holistic care. Founded by David Dardashti, the clinic leverages extensive clinical experience to provide a safe, medically supervised environment for profound psycho-spiritual healing and neurological reset, offering a definitive interruption to the cycle of addiction.
